Are ongoing trials on hematologic malignancies still excluding older subjects?
نویسندگان
چکیده
منابع مشابه
Are ongoing trials on hematologic malignancies still excluding older subjects?
vision of the possible mechanism(s) involved in the hemolytic crisis brought on by other comorbid conditions, such as sepsis. Along the same lines, there is evidence that the HbF levels, an important regulatory mechanism of SCA severity and hemolysis, govern MP concentration by acting on specific MP subtypes. We can imagine that, in SCA children, a storm of various (mainly platelet-derived) pro...
متن کاملHematologic Malignancies
Touch MEdical MEdia 43 Multiple myeloma (MM) is an incurable plasma cell disease that comprises 1 % of all cancers and 10 % of hematologic malignancies. It primarily affects older individuals—the median age at the moment of diagnosis is 70 years—and two-thirds of multiple myeloma patients are over 65 years of age when they are first diagnosed. The outcome of MM patients has significantly improv...
متن کاملHematologic Malignancies in Pregnancy
Cancer and especially hematological cancer during pregnancy is infrequent and its management is difficult for patients and their families, but also for their physicians since two lives with different priorities have to be considered. Treatment should adhere the standard treatment for the specific type and stage of cancer. Small adaptations can be considered in order to avoid adverse effects on ...
متن کاملp53 in hematologic malignancies.
T HE p53 HAS BEEN CHOSEN as molecule of the year for 1993 by the journal Science.' The protein's illustrious history began quietly in 1979, when a 53-kD eukaryotic protein was shown to bind to SV40 large T The protein was named p53 because of its size. Initial studies suggested that p53 was an oncogene because it could transform rodent ~ e l l s . ~ ' ~ The p53 genes used in these studies h...
متن کاملCD44 and hematologic malignancies.
The expression of CD44 was upregulated in some hematological malignancies and is associated with metastasis and prognosis. The ligation of CD44 with specific monoclonal antibodies can trigger terminal differentiation of leukemic blasts in some subtypes, so it is probable to develop an anti-CD44 based differentiation therapy in leukemia. The effects of CD44 and its monoclonal antibodies are disc...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Haematologica
سال: 2013
ISSN: 0390-6078,1592-8721
DOI: 10.3324/haematol.2013.087601